Frequently Asked Questions
The market is segmented based on , By Indication (Bronchitis, Pneumonia, Sinusitis, Tonsillitis/Pharyngitis), Drug Type (Telithromycin, Cethromycin, Solithromycin), Microorganism (Streptococcus Pneumoniae, Haemophilus Influenzae, Moraxella Catarrhalis, Chlamydophila Pneumoniae, and Mycoplasma Pneumoniae), Population Type (Children and Adults), Disease Type (Mild and Severe), Dosage Type (Oral and Parenteral), Mode of Purchase (Over the Counter and Prescription), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.
.
The Global Ketolides Market size was valued at USD 3.00 USD Billion in 2022.
The Global Ketolides Market is projected to grow at a CAGR of 4% during the forecast period of 2023 to 2030.
The major players operating in the market include F. Hoffmann, La Roche Ltd, Novartis AG, Eli Lilly and Company, Pfizer , Merck & Co. , Bristol, Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Abbott, Alembic Pharmaceuticals Limited, WOCKHARDT.
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
